17 MAR 2006

U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE ORM PTO-1390 (Modified) REV. 7-2005)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

19555

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/572418

22.

PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/SE2005/000096 28 January 2005 (28.01.2005) 30 January 2004 (30.01.2004) * TITLE OF INVENTION **HCV NS-3 SERINE PROTEASE INHIBITORS** APPLICANT(S) FOR DO/EO/US Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Susana Ayesa, Bjorn Classon, Lazlo Rakos and Bertil Samuelsson Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. \Box The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. is attached hereto (required only if not communicated by the International Bureau). \boxtimes has been communicated by the International Bureau. b. \boxtimes is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 6. is attached hereto. a. has been previously submitted under 35 U.S.C. 154(d)(4). b. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) 7. X are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. \boxtimes An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10 Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 11. A copy of the International Search Report (PCT/ISA/210). \boxtimes 12. Items 13 to 23 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14 \boxtimes A FIRST preliminary amendment. 15. A SECOND or SUBSEQUENT preliminary amendment. \Box 16. Ò 17. A substitute specification. A power of attorney and/or change of address letter. 18. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 19. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21. EV 861633003 US \mathbf{X} Express Mail Label No.

· . .

IAP9 Rec'd PCT/PTO 17 MAR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/SE2005/000096

19555

23. Other items or information:

ASSIGNEE NAME: MEDIVIR AB

ASSIGNEE ADDRESS: HUDDINGE, SWEDEN

*Continued from Priority Date Claimed: 19 May 2004 (19.05.2004) and 22 October 2004 (22.10.2004)

	fees have been s				œ.	300 8	S \$300.00	PTO USE
24. 🛭 Basic na	tional fee					300	\$300.00	
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article \$0							\$200.00	
All Other Situations.								
26. ☑ Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the as an International Searching Authority							\$ \$400.00	
All other situations						500	·	
TOTAL OF 24 25 and 26 =							\$ \$900.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets		per of each additional 50 of thereof (round up to a wh		RATE			
181 - 100 =	81 /50 =		2		x \$250.	00	\$ \$500.00	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).							\$ \$130.00	
CLAIMS	NUMBER F		NUMBER EXTRA		RATE	. 1		
Total claims	70	- 20 =	50	x	\$50.	.00	\$ \$2,500.00	
Independent clair	ms 2	- 3=	0	×	\$200	.00	\$ \$0.00	
	ENDENT CLAIMS	(if application	able)	+	\$360	.00	\$ \$360.00	
TOTAL OF ABOVE CALCULATIONS =							\$ \$4,390.00	
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.						\$ \$0.00	-	
SUBTOTAL =						AL =	\$ \$4,390.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).							\$ \$0.00	
TOTAL NATIONAL FEE =							\$ \$4,390.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$ \$0.00	
TOTAL FEES ENCLOSED =							\$ \$4,390.00	
							Amount to be	\$
							Amount to be	\$

!AP9 Rec'd PCT/PTO _ 7 MAR 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. 🔀	A check in the amount of \$ \$4,390.00 to cover the	ne above fees is enclosed.						
b. 🗖	Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	in the amount of \$	to cover the above fees.					
с. 🔀	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-1013/SSMP</u> . A duplicate copy of this sheet is enclosed.							
d. 🗆	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND	ALL CORRESPONDENCE TO:	"IVach AC	spe					
	mer No. 23389	SIGNATURE	SIGNATURE //					
	y, Scott, Murphy & Presser, P.C.	Mark J. Cohen	Mark J. Cohen NAME 32,211 REGISTRATION NUMBER					
	arden City Plaza, Suite 300 en City, New York 11530	NAME						
	742-4343	32,211						
[•	REGISTRATION NUMB						
1		March 17, 2006						
1		DATE	DATE					

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Docket No. Applicant(s): Asa Rosenquist, et al. 19555 Application No. Filing Date Examiner Customer No. Group Art Unit Unassigned Herewith Unassigned 23389 Unassigned **HCV NS-3 SERINE PROTEASE INHIBITORS** Invention: I hereby certify that the following correspondence: New U.S. Patent Application under 35 U.S.C. 371 (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 17, 2006 (Date) Mark J. Cohen (Typed or Printed Name of Person Mailing Correspondence) \$: P (Signature of Person Mailing Correspondence) EV 861633003 US ("Express Mail" Mailing Label Number) Note: Each paper must have its own certificate of mailing.